Evidence map›Paper›PMID 37488476›Full record

Observational studyBMC gastroenterology2023

A study on prevention of bleeding complications using lusutrombopag for safe RFA in patients with hepatocellular carcinoma with low platelet counts: prospective observational study.

Hideo Yoshida, Takamasa Ohki, Mineo Kanezaki, Takuma Teratani, Shinpei Sato, Shuntaro Obi, Takahisa Sato, Masatoshi Akamatsu, Koji Uchino, Hiroyoshi Taniguchi

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Hideo YoshidaDept. of Gastroenterology and Hepatology, Japanese Red Cross Medical Center, Tokyo, Japan. yoshida_hideo@med.jrc.or.jp.
Takamasa OhkiDivision of Gastroenterological Medicine, Mitsui Memorial Hospital, Tokyo, Japan.
Mineo KanezakiDept. of Gastroenterology, NTT Medical Center Tokyo, Tokyo, Japan.
Takuma TerataniDept. of Gastroenterology, NTT Medical Center Tokyo, Tokyo, Japan.
Shinpei SatoDept. of Gastroenterology and Hepatology, Kyoundo Hospital, Tokyo, Japan.
Shuntaro ObiDept of Gastroenterology, Teikyo University Chiba Medical Center, Ichihara, Chiba, Japan.
Takahisa SatoDept of Gastroenterology, Teikyo University Chiba Medical Center, Ichihara, Chiba, Japan.
Masatoshi AkamatsuDept. of Gastroenterology, JR Tokyo General Hospital, Tokyo, Japan.
Koji UchinoDept. of Gastroenterology and Hepatology, Japanese Red Cross Medical Center, Tokyo, Japan.
Hiroyoshi TaniguchiDept. of Gastroenterology and Hepatology, Japanese Red Cross Medical Center, Tokyo, Japan.
Japanese Red Cross Medical Center · JPNTT Medical Center · JPTeikyo University Chiba Medical Center · JPJR Tokyo General Hospital · JPMitsui Memorial Hospital · JPOgikubo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlatelet (PLT) transfusion was the most practical way to increase patients' PLT counts before invasive hepatic procedures such as radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). A novel drug that raises the PLT count by acting on the thrombopoietin receptor has recently become available.

methodsLusutrombopag 3 mg was administered daily for 7 days to patients who underwent RFA for liver tumors with low PLT counts (< 50,000 PLT µL

resultsLusutrombopag was administered to 91 patients, with a median age of 71 years (range 51-86). Forty-two patients had hepatitis C, 12 had hepatitis B, 21 had alcoholic liver disease, 11 had nonalcoholic steatohepatitis, and five had other diseases. The median Child-Pugh score was 7 (range 5-11). Thirty-seven patients had stage I tumors, 41 had Stage II, 12 had stage III, and one had stage IV. PLT count was elevated from 4.4 × 10

conclusionsLusutrombopag administration before RFA was effective and seemed to be relatively safe for hepatocellular carcinoma patients with low PLT counts.

trial registrationThis study was approved by Japanese Red Cross Medical Center Institutional Reseach Comittie (#862, 07/03/2016), and was registered in a publically accessible primary register (#UMIN000046629, registered date: 14/01/2022).

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAgedAged, 80 and overCinnamatesHumansMiddle AgedPlatelet CountThiazolesCinnamateslusutrombopagThiazolesCirrhosisHepatitisHepatocellular carcinomaInvasive procedureLiver tumorsLocolegional therapyLusutrombopagPlatelet countRadiofrequency ablationThrombopoietin receptor

Identifiers

PMID37488476
PMCPMC10364390
OpenAlexW4385201587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.